1.25
+0.03(+2.46%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.22 |
| Day High | 1.29 |
| Day Low | 1.2 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Volume | 3M |
| Average Volume | 3.1M |
| Market Cap | 273.41M |
| PE | -1.02 |
| EPS | -1.22 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.99 |
| Change | 0.03 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $50 as of June 25, 2025 at a share price of $1.25. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $28.42 as of June 25, 2025 at a share price of $1.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
GlobeNewswire Inc.
Jun 01, 2025 2:45 PM GMT
Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
May 23, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease,
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
GlobeNewswire Inc.
May 22, 2025 9:17 PM GMT
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease,